Get the Stockscreener App
3.08
3.14%
-0.10
After Hours:
3.11
0.03
+0.97%
Insight Molecular Diagnostics Inc stock is traded at $3.08, with a volume of 72,606.
It is down -3.14% in the last 24 hours and up +22.71% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
See More
Previous Close:
$3.18
Open:
$3.19
24h Volume:
72,606
Relative Volume:
3.17
Market Cap:
$88.15M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+24.19%
1M Performance:
+22.71%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.935
$3.215
1-Week Range:
$2.4034
$3.2998
52-Week Range:
$2.33
$3.2998
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.08 | 85.86M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
iMDx launches 5,000-patient registry to study transplant rejection test - Investing.com
iMDx launches 5,000-patient registry to study transplant rejection test By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (IMDX) Launches New Patient Regist - GuruFocus
IMDX Advances GraftAssureDx Clinical Trial for Transplant Rejection Test - GuruFocus
Insight Molecular Diagnostics Inc. Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - MarketScreener
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - GlobeNewswire
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database - The Manila Times
50,000 Samples: iMDx's Massive Registry to Transform $1B Transplant Testing Market with Novel Protocol - Stock Titan
Insight Molecular Diagnostics Inc. shares rise 1.62% premarket after Myriad Genetics announces positive MRD test results. - AInvest
Molecular Diagnostics Market: Applications, Growth, and Future Trends - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 1.78% intraday after QIAGEN gains U.S. clearance for higher-throughput syndromic testing system. - AInvest
iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire
iMDx Announces Participation in NYC Investment Conferences - AInvest
Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan
iMDx CFO Andrea James discusses democratizing molecular diagnostics in podcast episode. - AInvest
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener
HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.
Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest
Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest
Molecular Diagnostics Market Evolving Rapidly from 2025 to 2032 | F. Hoffmann-La Roche Ltd, Illumina, Inc. - openPR.com
Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest
Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest
IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks
Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest
Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener
Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest
Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com Nigeria
Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com India
Insight Molecular Diagnostics: Promising Future with GraftAssureIQ and Strategic Expansion - TipRanks
Insight Molecular Diagnostics: Q2 Earnings Snapshot - Connecticut Post
Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log
Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com Canada
Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx L - GuruFocus
IMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - 富途牛牛
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc.Common Stock (Nasdaq:IMDX) Stock Quote - FinancialContent
Molecular Diagnostics Market Overview: Growth Factors to 2035 - MarketReports.us
PCR Molecular Diagnostics Market Global Forecast 2025–2032: Sector-Wise Insights - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results. - AInvest
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - The Manila Times
iMDx to Release Second Quarter 2025 Results on August 11, - GlobeNewswire
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
There is no financial data for Insight Molecular Diagnostics Inc (IMDX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):